Kymanox

Kymanox is a life sciences consultancy that offers engineering, scientific and compliance support to companies exclusively in the biotechnology, pharmaceutical, medical device and combination product industries throughout the product lifecycle from early development to postmarket.

Associated Companies

NEUMA

HEADQUARTER
Kymanox Corporation
430 Davis Drive, Suite 300
Morrisville
NC 27560-6802
United States

Phone / Contact

T: +1 919 246 4896
E: [email protected]

Connect

Kymanox is a life science consultancy that offers engineering, scientific and compliance support to companies exclusively in the biotechnology, pharmaceutical, medical device and combination product industries. Kymanox’s team, which has diverse expertise, helps clients navigate commercialisation challenges that arise throughout the product lifecycle from early development to postmarket.

Kymanox is privately held and was founded in 2004.

In 2021 Kymanox acquired engineering services company Neuma.

Articles by Kymanox

ROUNDTABLE: DISCUSSION ON ANTI-OBESITY TREATMENTS

Stephen M Perry, Mathias Romacker and Andreas Schneider tackle the subject of GLP-1s and related obesity-targeted injectable therapeutics and the enormous impact they are having and are expected still to have on drug delivery and the wider pharmaceutical sector.

Interview: Kymanox Executive Advisors Mathias Romacker, Fran DeGrazio & Paul Jansen

Mathias Romacker, Fran DeGrazio and Paul Jansen sit down with Guy Furness, to discuss what it is that has driven Kymanox’s rapid rise in the drug delivery space and what makes the consulting company’s model so successful, as well as to share their expertise on a variety of topics in an illuminating discussion, including connectivity, how large and small drug developers engage with consultancies, 5 mL autoinjectors and the interface between drug primary packaging and delivery devices.

UNDERSTANDING YOUR PROCESS RELIABILITY: COMPLIANCE CONSIDERATIONS FOR EMERGENCY-USE DELIVERY SYSTEMS

Richard Motruk and Nathan Blazei discuss the issues to be considered in light of the US FDA’s tightened reliability standards for emergency-use autoinjectors.

INTERVIEW WITH STEPHEN M PERRY AND NICHOLAS CICCARELLI

Stephen Perry and Nicholas Ciccarelli discuss the August 2021 acquisition of Neuma by Kymanox, highlighting how the acquisition has positioned Kymanox to lead the development of particularly complex drug delivery systems and cutting-edge medical device technologies, providing additional services to progress combination products to market.

Top